Study of IMC-1121B (Ramucirumab) With Best Supportive Care in Participants With Gastric Cancer and Adenocarcinoma
Status:
Completed
Trial end date:
2015-12-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to gather information about the use of an investigational drug
called Ramucirumab in adenocarcinomas of the stomach or gastroesophageal junction.